First, the honesty
This is the science Buta-8 is built on. We’re deliberately detailed about the mechanism and deliberately strict about proof.
The most important sentence on this page: the Buta-8 blend itself hasn’t been clinically tested yet. Everything below is ingredient- and mechanism-level evidence. Proving what the finished blend does in real people is the job of our planned pilot. We won’t present ingredient evidence as product evidence.
The problem has two halves
Fibre is the most under-consumed nutrient in the modern diet. In the US, around 95% of adults fall short; average intake is ~16 g a day against a recommended 25–38 g. A low-fibre diet doesn’t just slow you down — it limits the fermentable material the gut microbiome runs on.
The second half is why people who try to fix it give up: fast-fermenting fibres (inulin, FOS, GOS) — the ones most “prebiotic” blends are built from — are a common cause of gas and bloating. A product can be scientifically sound and still fail if you quit on day four. Tolerability isn’t a footnote; it’s half the problem.
Fibre is not one thing
Different fibres do different jobs. Buta-8 is built across the functional spectrum, not on a single fibre:
- Psyllium — a viscous, gel-forming fibre; barely fermented; it bulks and softens, and moderates the fermentation of the fibres alongside it.
- Chicory inulin — fast-fermenting in the upper colon; the prebiotic workhorse, but high-gas on its own.
- Resistant potato starch — slowly fermented, further down; unlocked most effectively by a keystone bacterium.
- Acacia — the slowest, gentlest, lowest-gas of the fermentable fibres.
- Jamun & baobab — two whole-fruit botanicals that add insoluble fibre (the bulking kind your body doesn’t ferment) and polyphenols.
The three fermentable fibres are paced fast → slow across the colon, so the substrate supply is staggered rather than dumped — which is also part of why it’s gentler. Between the four fibres and the two fruits, the blend combines viscous, fermentable, and insoluble fibre contributions.
What decides a fibre’s job
Why does psyllium soothe while inulin ferments hard? It comes down to three things about how a fibre behaves in the colon — and they’re what we used to assign each fibre its role.
A fibre’s job ≈ how fast it ferments × how completely × which microbes it feeds
Speed decides where in the colon it acts; completeness decides how much short-chain fatty acid it yields; which microbes it recruits decides which acid you get. The first two only correlate with butyrate — the third is what actually sets it.
Run the four fibres through it and the roles fall out:
| Fibre | Ferments | Intensity | Its job |
|---|---|---|---|
| Chicory inulin | Fast | High | The fuel |
| Resistant starch | Slow | High | The engine |
| Acacia | Slow | Moderate | Gentle filler |
| Psyllium | Barely | Low | The gel |
- Resistant starch — the engine. Slow and deep, and among the most butyrate-favouring of the fibres: it recruits the bacteria that make butyrate. The catch is it’s unlocked most effectively once a keystone degrader gets to work (see the relay, below).
- Chicory inulin — the fuel. Fast and acetate-rich. On its own it’s gassy; in the blend its job is to keep the acetate pool full for the engine to draw on. We use long-chain inulin, not the short-chain kind (see below).
- Psyllium — the gel. Barely fermented; its job is viscosity and tolerability, not short-chain fatty acids. It’s the largest single fibre in the scoop, by design.
So the blend isn’t a longer ingredient list. It’s four fibres each doing a job the others can’t — an engine, its fuel, a gentle filler, and a gel to hold the whole thing steady.
Why we didn’t reach for FOS
The quickest way to put a big “prebiotic” number on a label is FOS (fructo-oligosaccharides): it’s cheap, mildly sweet, dissolves clear, and feeds bifidobacteria reliably. But FOS is a short-chain inulin-type fructan — shorter chains ferment even faster and higher up, which is exactly the recipe for gas, and it’s a lead member of the FODMAP group people cut out to stop bloating. FOS would buy a better-looking ingredient line and a worse experience. We used long-chain inulin for the prebiotic pull, kept the dose modest, and balanced it with psyllium — the opposite of the FOS shortcut.
Gentle by design
Here’s the mechanism behind “gentle.” In a randomised, MRI-controlled trial, taking psyllium together with inulin produced less colonic gas than inulin alone (Gunn et al., Gut 2022): the viscous psyllium gel slows and redistributes the fermentation, so gas is produced gradually and cleared rather than building up.
Two honest notes: the effect is kinetic (it slows the rate, it doesn’t “cancel” gas), and that trial used 20 g each — far above Buta-8’s 1.45 g inulin and 2.80 g psyllium. So the mechanism is established; Buta-8 applies it at much lower doses and a conservative ratio, keeping psyllium at or above the inulin load.
How butyrate is actually made — the relay
The simple story is “fibre → bacteria → butyrate.” The real one is a relay between different bacteria:
- Primary degraders break fibre down and release acetate, the simplest short-chain fatty acid.
- Butyrate producers (Faecalibacterium prausnitzii, Roseburia) take up that acetate and turn it into butyrate — in studied acetate-utilising producers, drawing 56–91% of the butyrate carbon from acetate made by other bacteria (Duncan et al., 2002, 2004).
And some fibres lean on a functioning community: resistant starch is unlocked most effectively by a keystone degrader, Ruminococcus bromii (Ze et al., 2012).
It’s not enough to have the butyrate-makers present — you need the bacteria that feed them, and a range of fibres to keep the acetate pool full. That’s the case for a diverse blend over a single fibre. Buta-8 supplies a range of fibres relevant to that relay; it doesn’t install the bacteria, and whether the finished blend shifts these markers in people still needs measuring.
Why not just take a butyrate pill?
Because fermenting fibre is the body’s own way of making butyrate — produced continuously, in the distal colon, right next to the cells that use it. A butyrate capsule delivers, at best, one molecule. Dietary fibres, depending on type and dose, also yield acetate and propionate and can support microbial diversity, regularity, fullness and a gentler post-meal glucose curve. The molecule isn’t the meal.
We don’t claim Buta-8 raises butyrate more than a direct-butyrate product — we feed the body’s own continuous production, alongside the other things dietary fibre can do.
Butyrate is the fuel of the gut wall
Butyrate is the preferred energy source of the cells lining your colon — they preferentially use butyrate, commonly cited as supplying roughly 60–70% of their energy (Roediger 1980; Donohoe et al., 2011). A fibre-poor diet doesn’t just slow transit; it under-fuels the gut wall. A well-fuelled lining maintains a tighter barrier (Peng et al., 2009). We don’t claim Buta-8 “reduces inflammation” — only that the mechanism by which fibre supports the barrier is well characterised.
The longevity link — a real mechanism, not a promise
Buta-8 is named for butyrate, and this is where we’re most careful. The honest split: the mechanism is genuinely citable; the outcome on a person is not.
What’s solid: butyrate is a textbook epigenetic regulator (an HDAC inhibitor; Candido et al., 1978), it’s studied for anti-inflammatory signalling (regulatory-T-cell induction; Furusawa et al., 2013; Arpaia et al., 2013) and mitochondrial pathways, and higher dietary fibre intake is robustly associated with lower all-cause mortality (around 7% lower per extra 8 g/day; Reynolds et al., Lancet 2019).
What we will never say: that butyrate is proven to extend human lifespan or change ageing-related outcomes in people. No human study shows that — the lifespan data are in flies, worms and diseased mice, often using HDAC-inhibitor drugs, not dietary butyrate. Buta-8 makes no longevity promise on you. We explain the engine; we never guarantee the destination.
The plant layer
Some plant compounds act on your gut bacteria, which convert them into the active molecule — the cleanest example is ellagitannins → urolithin A, linked to mitophagy (Ryu et al., 2016; Andreux et al., 2019). Only about 40% of people produce meaningful urolithin A, and the difference is microbiome composition (Tomás-Barberán et al., 2017) — another reason diversity matters. Jamun and baobab add to the polyphenol pool — and, as whole fruits, a little insoluble fibre; at Buta-8’s sub-gram doses we present the polyphenol contribution as a direction of travel, not a product claim. This illustrates microbiome-dependent polyphenol metabolism in general — we don’t claim jamun or baobab at these doses produce urolithin A or change mitophagy.
What’s in it
| Per 8 g scoop | Amount |
|---|---|
| Chicory inulin (Cichorium intybus) | 1.45 g |
| Resistant potato starch (Solanum tuberosum) | 0.96 g |
| Acacia / gum arabic (Acacia senegal) | 1.50 g |
| Psyllium husk (Plantago ovata) | 2.80 g |
| Baobab (Adansonia digitata) | 0.43 g |
| Jamun (Syzygium cumini) | 0.48 g |
| + taste: erythritol + monk fruit, citric acid | 0.38 g |
| Total | 8.0 g · ≈6 g fibre |
About 6 g fibre and ~15 kcal per scoop, low sugar, plant-based. Every gram disclosed — no proprietary blend.
8 g is a contribution, not a cure
Two kinds of dose-response matter. Threshold effects need a minimum dose to fire — for example, psyllium’s cholesterol effect needs ≥7 g/day on its own, which Buta-8 deliberately doesn’t deliver or claim. Cumulative effects build through the day — fibre feeding microbiome diversity and the butyrate pool. Buta-8 lives in the cumulative register: 8 g/day (~6 g fibre) is a meaningful daily contribution toward closing the fibre gap, roughly 40–65% of the typical shortfall — not a clinical monodose of any single ingredient.
What’s proven, what’s mechanism, what’s not
We tag our own claims so you don’t have to:
Established
The fibre gap. Viscous fibre slows gastric emptying. Psyllium + inulin produces less gas than inulin alone. The cross-feeding relay. Butyrate fuels the cells lining the colon. Higher fibre intake tracks with lower mortality.
Mechanism — designed-for, not yet measured on the blend
Buta-8’s tolerability edge at its specific doses; the diversity → relay rationale; the cellular and antioxidant routes butyrate is studied for.
Not claimed
That Buta-8 raises butyrate in everyone, reduces inflammation, shifts your biology, or extends lifespan. That’s what the pilot is for.
What the pilot will measure
An open-label daily-use pilot (target ~200, with continuous glucose monitoring): tolerability and adherence over four weeks, repurchase intent, taste, post-meal glucose, regularity and comfort, and — if feasible — faecal short-chain fatty acids on a subset. It will turn “true in general” into “observed for Buta-8.” It won’t establish clinical or longevity outcomes; those need randomised controlled trials. We’ll report it as what it is.
References
- Gunn D, et al. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in-vitro fermentation studies. Gut, 2022.
- Duncan SH, et al. Acetate utilization and butyryl-CoA:acetate-CoA transferase in butyrate-producing bacteria. Appl. Environ. Microbiol., 2002.
- Duncan SH, et al. Contribution of acetate to butyrate formation by human faecal bacteria. Br. J. Nutr., 2004.
- Ze X, et al. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J., 2012.
- Koh A, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 2016.
- Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa. Gut, 1980.
- Donohoe DR, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabolism, 2011.
- Peng L, et al. Butyrate enhances the intestinal barrier by facilitating tight-junction assembly via AMPK. J. Nutr., 2009.
- Marciani L, et al. Gastric response to increased meal viscosity assessed by MRI in humans. Am. J. Physiol. GI Liver Physiol., 2001.
- Reynolds A, et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet, 2019.
- Candido EPM, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell, 1978.
- Furusawa Y, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 2013.
- Arpaia N, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 2013.
- Kelly CJ, et al. Crosstalk between microbiota-derived SCFAs and intestinal epithelial HIF augments barrier function. Cell Host Microbe, 2015.
- Tomás-Barberán FA, et al. Urolithins, the rescue of “old” metabolites to understand a “new” concept: metabotypes. Mol. Nutr. Food Res., 2017.
- Ryu D, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat. Med., 2016.
- Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat. Metab., 2019.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
← Back to Buta-8